Company intelligence / Profile preview

OcuCure Therapeutics

Roanoke, Virginia, United Stateslvg.virginia.edu ↗

Ownership: Private
Employees: ~1
Development stage: Preclinical

Overview

OC-10X has demonstrated safety in a proof of concept human clinical trial and a proof of concept efficacy trial has been initiated. Phase I Study found that OC-10X can be safely applied topically in human eyes without adverse ocular or systemic effects[2][3].

Therapeutic areas: Ophthalmology
Modalities: Small moleculestopical eye drops
Industry: Biotech

Drug pipeline

1 asset

OC-10X

Beyond the preview

Go deeper on OcuCure Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OcuCure Therapeutics.

Explore the full profile